Prospective observational study to evaluate the efficacy and safety of PD-1/PD-L1 antibody by PK/PD/PGx analysis.

Prospective observational study to evaluate the efficacy and safety of PD-1/PD-L1 antibody by PK/PD/PGx analysis. - NCCH-1605

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000029994

Enrollment

210

Registered

2017-11-16

Start date

2016-11-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients aged 20 years or older who are diagnosed as inoperable or recurrent lung cancer and scheduled to receive anti PD-1/PD-L1 antibody.

Exclusion criteria

Exclusion criteria: Not applicable

Design outcomes

Primary

Measure	Time frame
Response Rate	—

Countries

Japan

Contacts

Public Contactygoto@ncc.go.jp

National Cancer Center Hospital Thoracic Oncology

ygoto@ncc.go.jp03-3542-2511

Outcome results